Quest Diagnostics Beats Q3 Estimates and Raises Full-Year 2026 Outlook

Key Facts

1Quest Diagnostics exceeded Q3 2026 earnings and revenue estimates.

2The company raised its full-year 2026 outlook citing strong testing demand and margin gains.

3DGX shares declined in pre-market trading despite the positive financial results.

Quest Diagnostics exceeded Q3 2026 earnings and revenue estimates. Zacks reported that the company raised its full-year 2026 outlook, citing strong testing demand and operational margin gains.

DGX shares declined in pre-market trading despite the positive financial results. The stock had closed at $238.93 on October 21, 2026, after reaching a day high of $240.56 and a low of $223.5.